The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology

Jonel Trebicka(Goethe University Frankfurt), Javier Fernández(European Foundation for the Study of Chronic Liver Failure), Mária Papp(University of Debrecen), Paolo Caraceni(University of Bologna), Wim Laleman(KU Leuven), Carmine Gambino(University of Padua), Ilaria Giovo, Frank Erhard Uschner(Goethe University Frankfurt), César Jiménez(Universitat Autònoma de Barcelona), Rajeshwar P. Mookerjee(The Royal Free Hospital), Thierry Gustot(Université Libre de Bruxelles), Agustı́n Albillos(Universidad de Alcalá), Rafael Bañares(Hospital General Universitario Gregorio Marañón), Martin Janíčko(University of Pavol Jozef Šafárik), Christian J. Steib(LMU Klinikum), Thomas Reiberger(Medical University of Vienna), Juan Acevedo(University Hospitals Plymouth NHS Trust), Pietro Gatti, William Bernal(King's College Hospital), Stefan Zeuzem(Goethe University Frankfurt), Alexander Zipprich, Salvatore Piano(University of Padua), Thomas Berg(Leipzig University), Tony Bruns(Universitätsklinikum Aachen), Flemming Bendtsen(Hvidovre Hospital), Minneke J. Coenraad(Leiden University Medical Center), Manuela Merli(Sapienza University of Rome), Rudolf Stauber(Medical University of Graz), Heinz Zoller(Innsbruck Medical University), José Presa Ramos(Association for the Development of Douro Viticulture), Cristina Solé(Hospital Clínic de Barcelona), Germán Soriano(Hospital de Sant Pau), Andrea De Gottardi(University Hospital of Bern), Henning Grønbæk(Aarhus University Hospital), Faouzi Saliba(Inserm), Christian Trautwein(Universitätsklinikum Aachen), Osman Özdoğan(Marmara University), Sven Francque(Antwerp University Hospital), Stephen Ryder(Nottingham University Hospitals NHS Trust), Pierre Nahon(Inserm), Manuel Romero‐Gómez(Hospital Universitario Virgen del Rocío), Hans Van Vlierberghe(Ghent University Hospital), Claire Francoz(Inserm), Michael P. Manns(Medizinische Hochschule Hannover), Elisabet García(European Foundation for the Study of Chronic Liver Failure), Manuel Tufoni(University of Bologna), Àlex Amorós(European Foundation for the Study of Chronic Liver Failure), Marco Pavesi(European Foundation for the Study of Chronic Liver Failure), Cristina Sánchez(European Foundation for the Study of Chronic Liver Failure), Anna Curto(European Foundation for the Study of Chronic Liver Failure), Carla Pitarch(European Foundation for the Study of Chronic Liver Failure), Antonella Putignano(Université Libre de Bruxelles), Esau Moreno(European Foundation for the Study of Chronic Liver Failure), Debbie L. Shawcross(King's College Hospital), Ferrán Aguilar(European Foundation for the Study of Chronic Liver Failure), Joan Clària(European Foundation for the Study of Chronic Liver Failure), Paola Ponzo, Christian Jansen(University Hospital Bonn), Zsuzsanna Vitális(University of Debrecen), Giacomo Zaccherini(University of Bologna), Boglárka Balogh(University of Debrecen), Vı́ctor Vargas(Universitat Autònoma de Barcelona), Sara Montagnese(University of Padua), Carlo Alessandria, Mauro Bernardi(University of Bologna), Pere Ginès(Hospital Clínic de Barcelona), Rajiv Jalan(The Royal Free Hospital), Richard Moreau(Inserm), Paolo Angeli(University of Padua), Vicente Arroyo(European Foundation for the Study of Chronic Liver Failure), Miriam Maschmeier, David Semela, Laure Elkrief, Ahmed M. Elsharkawy, Tamás Tornai, István Tornai, I Altorjay, Agnese Antognoli(University of Padua), Maurizio Baldassarre, Martina Gagliardi, Eleonora Bertoli, Sara Mareso(University of Padua), Alessandra Brocca, Daniela Campion, Giorgio Maria Saracco, Martina Rizzo, Jennifer Lehmann, Alessandra Pohlmann, Michael Praktiknjo(Medizinische Hochschule Hannover), Robert Schierwagen, Elsa Solà, Nesrine Amari, Miguel Rodriguez, Frederik Nevens, Ana Clemente(European Foundation for the Study of Chronic Liver Failure), Peter Jarčuška(University of Pavol Jozef Šafárik), Alexander L. Gerbes, Mattias Mandorfer, Christoph Welsch, Emanuela Ciracì, Vish Patel, Cristina Ripoll(European Foundation for the Study of Chronic Liver Failure), Adam Herber, Paul Horn, Karen Vagner Danielsen, Lise Lotte Gluud, Jelte J. Schaapman, Oliviero Riggio, Florian Rainer, Jörg Tobiasch Moritz, Mónica Mesquita, Edilmar Alvarado‐Tápias, O Akpata, Peter Lykke Eriksen(University of Pavol Jozef Šafárik), Didier Samuel, Sylvie Tresson, Pavel Strnad, Roland Amathieu, Macarena Simón‐Talero, Francois Smits, Natalie Van den Ende, Javier Martínez(European Foundation for the Study of Chronic Liver Failure), Rita Garcia(European Foundation for the Study of Chronic Liver Failure), Daniel Markwardt, Harald Rupprechter, Cornelius Engelmann
Journal of Hepatology
July 13, 2020
Cited by 496Open Access
Full Text

Abstract

BACKGROUND & AIMS: Acute decompensation (AD) of cirrhosis is defined as the acute development of ascites, gastrointestinal hemorrhage, hepatic encephalopathy, infection or any combination thereof, requiring hospitalization. The presence of organ failure(s) in patients with AD defines acute-on-chronic liver failure (ACLF). The PREDICT study is a European, prospective, observational study, designed to characterize the clinical course of AD and to identify predictors of ACLF. METHODS: A total of 1,071 patients with AD were enrolled. We collected detailed pre-specified information on the 3-month period prior to enrollment, and clinical and laboratory data at enrollment. Patients were then closely followed up for 3 months. Outcomes (liver transplantation and death) at 1 year were also recorded. RESULTS: Three groups of patients were identified. Pre-ACLF patients (n = 218) developed ACLF and had 3-month and 1-year mortality rates of 53.7% and 67.4%, respectively. Unstable decompensated cirrhosis (UDC) patients (n = 233) required ≥1 readmission but did not develop ACLF and had mortality rates of 21.0% and 35.6%, respectively. Stable decompensated cirrhosis (SDC) patients (n = 620) were not readmitted, did not develop ACLF and had a 1-year mortality rate of only 9.5%. The 3 groups differed significantly regarding the grade and course of systemic inflammation (high-grade at enrollment with aggravation during follow-up in pre-ACLF; low-grade at enrollment with subsequent steady-course in UDC; and low-grade at enrollment with subsequent improvement in SDC) and the prevalence of surrogates of severe portal hypertension throughout the study (high in UDC vs. low in pre-ACLF and SDC). CONCLUSIONS: Acute decompensation without ACLF is a heterogeneous condition with 3 different clinical courses and 2 major pathophysiological mechanisms: systemic inflammation and portal hypertension. Predicting the development of ACLF remains a major future challenge. CLINICALTRIALS. GOV NUMBER: NCT03056612. LAY SUMMARY: Herein, we describe, for the first time, 3 different clinical courses of acute decompensation (AD) of cirrhosis after hospital admission. The first clinical course includes patients who develop acute-on-chronic liver failure (ACLF) and have a high short-term risk of death - termed pre-ACLF. The second clinical course (unstable decompensated cirrhosis) includes patients requiring frequent hospitalizations unrelated to ACLF and is associated with a lower mortality risk than pre-ACLF. Finally, the third clinical course (stable decompensated cirrhosis), includes two-thirds of all patients admitted to hospital with AD - patients in this group rarely require hospital admission and have a much lower 1-year mortality risk.


Related Papers

No related papers found

Powered by citation graph analysis